Menu

Highlights FY 2016-17

Revenue

60,063 million

EBITDA

13,701 million

PAT

5,756 million

International Revenue

7 1%

Segmental Revenue Analysis FY 2016-17

Pharmaceuticals

31,167 million

52% Revenue
Mix

Life Science Ingredients

27,076 million

45% Revenue
Mix

Drug Discovery Solutions

1,820 million

3% Revenue
MIx